Patents by Inventor Kandasamy Hariharan
Kandasamy Hariharan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8147829Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.Type: GrantFiled: September 14, 2009Date of Patent: April 3, 2012Assignee: Biogen Idec MA Inc.Inventors: Kandasamy Hariharan, Scott Glaser, Ellen Garber, Christilyn Graff, Christopher L. Reyes, Stephen Demarest
-
Publication number: 20100203010Abstract: Compositions comprising CD80-targeted therapeutics and methods of using these compositions are provided for the treatment of a disease or disorder in which CD80-expressing cells or regulatory T cell function contribute to or exacerbate the associated pathology.Type: ApplicationFiled: March 28, 2008Publication date: August 12, 2010Applicant: BIOGEN IDEC INC.Inventors: Kandasamy Hariharan, Shabnam Tangri, Arturo Molina
-
Publication number: 20100189716Abstract: Compositions comprising CD80 antagonists and methods using these compositions are provided for the treatment of Hodgkins lymphoma. More particularly, the disclosed CD80 antagonists may be used to induce apoptosis or lysis of Hodgkins Reed-Sternberg (HRS) cells, or to inhibit HRS cell activities that promote tumor development or progression.Type: ApplicationFiled: March 28, 2008Publication date: July 29, 2010Applicant: BIOGEN IDEC INC.Inventors: Arturo Molina, Kandasamy Hariharan, Steffan Ho
-
Publication number: 20100098710Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.Type: ApplicationFiled: September 14, 2009Publication date: April 22, 2010Applicant: Biogen Idec MA Inc.Inventors: Kandasamy Hariharan, Scott Glaser
-
Publication number: 20100099147Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.Type: ApplicationFiled: September 14, 2009Publication date: April 22, 2010Applicant: Biogen Idec MA Inc.Inventors: Kandasamy Hariharan, Scott Glaser
-
Publication number: 20090291088Abstract: The invention relates to methods of treatment using combination therapy wherein a variety of therapeutically useful compounds may be combined with antibodies which bind to insulin-like growth factor receptor-1 (IGF-1R). Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention particularly includes methods of treating cancer using combination therapies with IGF-1R antibodies.Type: ApplicationFiled: April 10, 2009Publication date: November 26, 2009Applicant: Biogen Idec MA Inc.Inventors: Kandasamy Hariharan, Jianying Dong
-
Patent number: 7612178Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.Type: GrantFiled: March 28, 2007Date of Patent: November 3, 2009Assignee: Biogen Idec MA IncInventors: Kandasamy Hariharan, Scott Glaser, Ellen Garber, Christilyn Graff, Christopher L. Reyes, Stephen Demarest
-
Publication number: 20090130105Abstract: The instant invention is based, at least in part on the finding that binding molecules which bind to different epitopes within IGF-1R result in improved IGF-1 and/or IGF-2 blocking capabilities when compared to binding molecules that bind to a single IGF-1R epitope. The instant invention provides compositions that bind to multiple epitopes of IGF-1R, for example, combinations of monospecific binding molecules or multispecific binding molecules (e.g., bispecific molecules). Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize IGF-1R signaling are also provided.Type: ApplicationFiled: August 28, 2008Publication date: May 21, 2009Applicant: Biogen Idec MA Inc.Inventors: Scott Glaser, Stephen Demarest, Brian Robert Miller, Kandasamy Hariharan, Steffan Ho, Jianying Dong, Alexey Alexandrovich Lugovskoy
-
Publication number: 20090092614Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies capable of synergistically inhibiting the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2), to bind to IGF-1R; as well as fragments, variants and derivatives of such antibodies. Antibodies of the invention produce such synergistic effects via allosteric and/or competitive inhibition of IGF-1R ligand binding.Type: ApplicationFiled: August 28, 2008Publication date: April 9, 2009Applicant: Biogen Idec MA Inc.Inventors: Stephen Demarest, Kandasamy Hariharan
-
Publication number: 20080227198Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.Type: ApplicationFiled: August 17, 2007Publication date: September 18, 2008Applicant: Biogen Idec Inc.Inventors: Kandasamy Hariharan, Nabil Hanna
-
Publication number: 20080226626Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.Type: ApplicationFiled: August 17, 2007Publication date: September 18, 2008Applicant: Biogen Idec Inc.Inventors: Kandasamy Hariharan, Nabil Hanna
-
Publication number: 20080213260Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).Type: ApplicationFiled: August 17, 2007Publication date: September 4, 2008Applicant: Biogen Idec Inc.Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
-
Publication number: 20080213168Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).Type: ApplicationFiled: August 17, 2007Publication date: September 4, 2008Applicant: Biogen Idec Inc.Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
-
Publication number: 20080213167Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).Type: ApplicationFiled: August 17, 2007Publication date: September 4, 2008Applicant: Biogen Idec Inc.Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
-
Publication number: 20080171056Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).Type: ApplicationFiled: August 17, 2007Publication date: July 17, 2008Applicant: Biogen Idec Inc.Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
-
Patent number: 7319139Abstract: Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for two distinct antigens (heterodimers). In preferred embodiments the antibody molecules comprising the dimers are non-covalently associated.Type: GrantFiled: January 29, 2002Date of Patent: January 15, 2008Assignee: Biogen Idec, Inc.Inventors: Gary R Braslawsky, Nabil Hanna, Paul Chinn, Kandasamy Hariharan
-
Publication number: 20070280881Abstract: Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for two distinct antigens (heterodimers). In preferred embodiments the antibody molecules comprising the dimers are non-covalently associated.Type: ApplicationFiled: January 29, 2002Publication date: December 6, 2007Inventors: Gary Braslawsky, Nabil Hanna, Paul Chinn, Kandasamy Hariharan
-
Publication number: 20070243194Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.Type: ApplicationFiled: March 28, 2007Publication date: October 18, 2007Applicant: Biogen Idec MA Inc.Inventors: Kandasamy Hariharan, Scott Glaser, Ellen Garber, Christilyn Graff, Christopher Reyes, Stephen Demarest
-
Publication number: 20070065436Abstract: Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response.Type: ApplicationFiled: August 14, 2006Publication date: March 22, 2007Applicant: Biogen Idec Inc.Inventors: Kandasamy Hariharan, Nabil Hanna
-
Publication number: 20070009519Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.Type: ApplicationFiled: July 21, 2006Publication date: January 11, 2007Applicant: Biogen Idec Inc.Inventors: Kandasamy Hariharan, Nabil Hanna